Macrophage cholesterol efflux pathway

The macrophage cholesterol efflux pathway refers to the cellular processes in which macrophages remove excess cholesterol, primarily through the action of transporters such as ATP-binding cassette transporter A1 (ABCA1), transporter G1 (ABCG1), and scavenger receptor B1 (SR-BI), by transferring cholesterol to extracellular acceptors like high-density lipoprotein (HDL) or apolipoprotein A-I[1][2][3][4]. This pathway is critical for preventing foam cell accumulation in atherosclerotic plaques and for overall cholesterol homeostasis. Rather than being a single molecular target, it describes an ensemble mechanism involving multiple proteins, making it unsuitable as a canonical drug target name. Targeting this pathway pharmacologically often involves modulating ABCA1, ABCG1, or nuclear receptors such as LXR or PPARs to enhance cholesterol efflux and reduce atherosclerotic risk[1][2][4]. Key point: The "Macrophage cholesterol efflux pathway" is a physiological process, not a discrete druggable protein, and corresponds to a set of targets, not a single canonical entity. If a specific target is required, ABCA1 (ATP-binding cassette transporter A1) is the prototypical molecular target in this context[2][3].

Other names

cholesterol efflux pathway in macrophagesmacrophage cholesterol effluxreverse cholesterol transport pathway (in macrophages)

Upregulation of ABCA1/ABCG1 expression (promoting cholesterol efflux); Enhancement of HDL-mediated cholesterol clearance.